Clinical Conversations

September 9th, 2014

Podcast 174: PARADIGM and Heart Failure

The PARADIGM-HF trial of LCZ696 — a novel compound that both blocks the renin-angiotensin system with an ARB component and blocks neprilysin’s degradation of natriuretic peptides — increased survival in heart failure by some 20% relative to enalapril. It seems to be a big deal, and the trial’s two principal authors have agreed to talk […]

---

July 10th, 2009

Podcast 49: Three RASS Study researchers discuss their findings on the lack of benefit of renin-angiotensin blockade in the primary prevention of diabetic nephropathy in Type 1 diabetes.

We talk with Drs. Michael Mauer, Ronald Klein, and Bernard Zinman about their paper in the July 2 New England Journal of Medicine reporting on the RASS study (Renin-Angiotensin System Study). They found that blockade of the renin-angiotensin system was not effective in the primary prevention of diabetic nephropathy in Type 1 diabetes. This week’s […]

---